Rhythm Pharmaceuticals SEC filings: 8-K

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KNov. 3, 2026, 8:10 a.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
AI summary, unreviewedRhythm Pharmaceuticals Q3 2026 net product revenue rises to $92.1 million, beating $84.6 million consensus; GAAP EPS $(0.61) beats $(0.74) estimate
8-KAug. 4, 2026, 7:49 a.m. ETView on SEC.gov
Results of operations and financial condition · Regulation FD disclosure · Other events · Financial statements and exhibits